Compare United States Natural Gas Fund (UNG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Natural Gas Fund vs GeneDx Holdings Corp — how do they compare? United States Natural Gas Fund trades at $11.01 (market cap $517.27M), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 3.9× United States Natural Gas Fund's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 29,485,537). Which is the better fit depends on your goals — on Pluang, investors hold United States Natural Gas Fund for 22 Days and GeneDx Holdings Corp for 19 Days on average.
| UNG | WGS | |
|---|---|---|
Market Cap | $517.27M | $2.02B |
Volume | 29,485,537 | 734,640 |
Sector | Commodities - Energy | Health |
52-Week High | $16.90 | $167.51 |
52-Week Low | $9.63 | $34.51 |
Typical Hold Time | 22 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UNG trades at $10.81, down 1.99% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong net income of $65.15M for 2024 despite zero revenue, with robust cash flow from operations of $47.54M. Recent news highlights natural gas market volatility driven by record production and geopolitical tensions.
The outlook is mixed: technical momentum supports near-term upside, but fundamental concerns arise from zero revenue and negative net cash flow. Risks include commodity price sensitivity and geopolitical factors affecting natural gas markets. Analyst sentiment leans bullish on technicals but requires fundamental improvement for sustained growth.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
